Neurelis is an innovation-driven neuroscience company that provides a differentiated approach to target unmet medical needs. Our application of novel technologies is designed to enhance therapeutic benefit and patient care.
We have reached a milestone in patient care with the first FDA-approved treatment from Neurelis.
Neurelis has a proprietary technology portfolio that includes Intravail®, ProTek®, and Hydrogel® for drug delivery enhancement. These three non-invasive drug delivery and stabilization technologies are applicable to a wide range of molecules including therapeutic proteins, peptides, and non-peptide large and small molecules. Our technologies offer exceptional potential value in enhancing drug development and clinical performance.